ReviewCurrent oncology reports2021
New Treatments for Recurrent Uterine Cancer.
Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Causal impact of obesity class stratification and endometrial cancer subtypes: an integrated Mendelian randomization and Global Burden of Disease Study 2021 analysis.International journal of surgery (London, England) · 2025Article
- Health inequality and improvement gap in the prevalence of gynecological cancers among perimenopausal women globally, 1990-2019.BMC public health · 2025Article
- Race- associated molecular differences in uterine serous carcinoma.Frontiers in oncology · 2024Article
- Risk-adjusted hazard analysis of survival after pulmonary metastasectomy for uterine malignancies in 319 cases.JTCVS open · 2023Article
- The Global, Regional, and National Uterine Cancer Burden Attributable to High BMI from 1990 to 2019: A Systematic Analysis of the Global Burden of Disease Study 2019.Journal of clinical medicine · 2023Article
- Anti-tumor effect of Wasabi component, 6-(methylsulfinyl) hexyl isothiocyanate, against endometrial carcinoma cells.Discover oncology · 2023Article
- Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature.Cancers · 2022Review
- Neural plasticity of the uterus: New targets for endometrial cancer?Women's health (London, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewEndometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years. RECENT
findingsNew targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.